Sign Up
Stories
Nanomedicine Leader Welcomes Chairman Altschuler
Share
Advancements in Cancer Treatment and Mar...
BioSenic's Phase 3 Study for Chronic GvH...
BioSenic's Progress and Patent
ANJESO Drug Insight and Market Forecast
Acelyrin Appoints Ken Lock as Chief Comm...
Afya Limited Expands Medical Seats in Br...
Overview
API
Dr. Steven M. Altschuler is appointed as Chairman of ViaNautis Bio, a genetic therapy-focused nanomedicine company, to drive its development. The company secured $25 million in a Series A funding round led by 4BIO Capital, BGF, and UCB Ventures.
Ask a question
How could the collaboration with venture capital firms like 4BIO Capital shape the future of genetic therapies in healthcare?
How might Dr. Altschuler's leadership impact the strategic direction of ViaNautis Bio?
What specific genetic therapy advancements is ViaNautis Bio aiming to achieve with the recent funding?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Apr 2024
Coverage